Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. is a clinical-stage biotechnology company whose core business model involves the development of novel pharmaceuticals. This process inherently requires extensive animal testing as part of preclinical research and regulatory submissions to the U.S. Food and Drug Administration. The company's public filings explicitly state that its drug development programs rely on laboratory and animal tests to support Investigational New Drug (IND) applications.

An FDA Form 483 inspection report documents an animal health inspection related to Windtree Therapeutics, indicating direct regulatory oversight of its animal research activities. Further, the company has been specifically identified by third-party observers, including Cruelty Free Investors, for its involvement in animal testing. As a pharmaceutical developer with no marketed products, its operations are fundamentally dependent on animal-based research to advance its pipeline, placing it within the scope of commercial animal exploitation.